Alternative targeted therapy for early HER2 positive breast cancer
| Data(s) |
01/02/2013
|
|---|---|
| Resumo |
Her2 (erbB2) receptor is overexpressed in around twenty percent of early breast cancer and historically conferred a poorer prognosis (1). Targeted anti-Her2 therapy has significantly improved outcomes for these women.<br /> |
| Identificador | |
| Idioma(s) |
eng |
| Publicador |
Gland Surgery |
| Relação |
http://dro.deakin.edu.au/eserv/DU:30052338/khasraw-alternativetargeted-2013.pdf http://dx.doi.org/10.3978/j.issn.2227-684X.2013.02.06 |
| Tipo |
Journal Article |
